Revolutionizing Cancer Treatment: A2 Biotherapeutics Secures $80M in Series C Funding

A2 Biotherapeutics is thrilled to announce a significant funding milestone of $80 million, a strategic investment that will expedite the company’s mission to revolutionize cancer treatment through innovative cell therapy. Founded in 2018 by visionary leaders Alexander Kamb, Michael Gallo, and Paul Kang, A2 is dedicated to transforming medicine by targeting solid tumors—a challenging frontier in the field. The latest funding round, which brings the total capital raised since inception to an impressive $136 million, comes from a consortium of esteemed investors, including The Column Group, Vida Ventures, and Hartford HealthCare Endowment. This financial boost will facilitate the advancement of A2's cutting-edge technology that engineers T cells to specifically recognize and attack tumor cells that have lost crucial genetic material, thereby enabling rapid and selective destruction of malignant cells while sparing healthy tissues. The implications of this innovative approach hold tremendous promise for patients facing daunting cancer diagnoses. With this new infusion of funds, A2 aims to accelerate clinical development, enhance research capabilities, and expand its team of experts dedicated to making a tangible impact in oncology. “This investment validates our approach and underscores the confidence our investors have in our vision to tackle the complexities of solid tumors,” said CEO Alexander Kamb. A2 Biotherapeutics epitomizes the future of personalized medicine, and with substantial resources backing its quest, the company is poised to break new ground in the fight against cancer.